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ABSTRACT
Introduction. Anti-tumor necrosis factor (TNF) agents are effective for several
immunologicconditions(rheumatoidarthritis(RA),Crohn’sdisease(CD),andpso-
riasis). The purpose of this study was to evaluate the efficacy and safety of anti-TNF
agentsviachartreview.
Methods. Single-site, retrospective cohort study that evaluated the efficacy and
safety of anti-TNF agents in veterans initiated between 2010 and 2011. Primary aim
evaluated response at 12 months post-index date. Secondary aims evaluated initial
responsepriorto12monthspost-indexdateandinfectionevents.
Results. A majority of patients were prescribed anti-TNF agents for CD (27%) and
RA (24%). Patients were initiated on etanercept (41%), adalimumab (40%), and in-
fliximab(18%)between2010and2011.Nodifferencesinpatientdemographicswere
reported. Response rates were high overall. Sixty-five percent of etanercept patients,
82% of adalimumab patients, and 59% of infliximab patients were either partial
or full responders, respectively. Approximately 16%, 11%, and 12% of etanercept,
adalimumab, and infliximab were non-responders, respectively. Infections between
thegroupswerenon-significant.Etanerceptandadalimumabpatientshadhigherbut
non-significantoddsofbeingaresponderrelativetoinfliximab.
Conclusions. Most patients initiated with anti-TNF agent were responders at 12
monthsfollow-upforallindicationsinaveteranpopulation.
Subjects Drugs and Devices, Epidemiology, Evidence Based Medicine, Health Policy
Keywords Tumor necrosis factor, Etanercept, Adalimumab, Certolizumab, Formulary manage-
ment, Cohort study, Rheumatoid arthritis, Crohn’s disease, Infliximab, Veterans
INTRODUCTION
In the past two decades, biologic therapies have reshaped how clinicians approached
chronic disease management (Agarwal, 2011a; Agarwal, 2011b; Ford et al., 2011;
Lichtenstein, Hanauer & Sandborn, 2009; Mayberry et al., 2013; Singh & Cameron, 2012).
Immunologic disorders such as rheumatoid arthritis (RA) and Crohn’s disease (CD)
have traditionally relied on oral pharmacotherapy for treatment of acute symptoms,
management, and remission. However, oral therapies were unable to provide long-term
control and disease progression resulting in relapse and hospital admission/surgery.
Biologic agents, such as monoclonal antibodies, target the host’s immune system to
attenuatetheself-destructiveimmuneresponse,whichisthecauseofRAandCD.Clinical
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admission/surgery (Bodger, 2002; Lundkvist, Kast¨ ang & Kobelt, 2008). More importantly,
biologic therapy has improved the quality of life for patients suffering with these chronic
diseases(Feaganetal.,2009;Staplesetal.,2011).
Monoclonalantibodies,inparticular,theanti-tumornecrosisfactor(TNF)agents,have
demonstrated significant reductions in disease symptoms, progression, and improvement
in patient quality of life (Feagan et al., 2009; Ford et al., 2011; Lundkvist, Kast¨ ang & Kobelt,
2008; Nixon, Bansback & Brennan, 2007; Ord´ as, Feagan & Sandborn, 2011). In several
studies, anti-TNF agents have increased the proportion of patients who experience
remission; thereby, controlling the disease and limiting permanent damage. In some
studies, remission duration has been reported for several years (Ancut ¸a et al., 2009; Emery
etal.,2010;VanderHeijdeetal.,2006).
RA is a systemic autoimmune disorder which is characterized by inflammation of the
synovial joints (Segal, Rhodus & Patel, 2008). RA affects about 0.5% to 1.0% of the US
population with a prevalence of 1.3 million (Gabriel & Michaud, 2009; Helmick et al.,
2008). The health burden of RA in the US was estimated to be 98 Disability Adjusted Life
Years(DALYS)lostper100,000population;and1RA-relateddeathper100,000population
(Lundkvist, Kast¨ ang & Kobelt, 2008). In the VA, there were a total of 1,694 RA-related
mortalities from 1999 to 2004 (Lee et al., 2007). The age-adjusted 5-year RA-related
mortality rate among patients with a single condition relative to no other condition was
6.05(95%confidenceinterval[CI][4.90,7.20])(Leeetal.,2007).Theaverageannualcosts
of RA per person in the US was $12,558 (adjusted for 2006 $US) (Lundkvist, Kast¨ ang &
Kobelt,2008).
The goal of therapy for patients with RA is to control and reduce the rate of degenera-
tion of the joints due to immunologic destruction by the host’s immune system (Agarwal,
2011a). In addition, quality of life and increased productivity are important milestones
for treatment. Anti-TNF agents have been reported to reduce the rate of radiographic
progression and improve short-term inflammatory symptoms (Bathon et al., 2000;
Breedveld et al., 2006; Choy et al., 2012; Emery et al., 2009; Keystone et al., 2008; Keystone
et al., 2009; Keystone et al., 2004; Klareskog et al., 2004; Maini et al., 1999; Moreland et
al., 1999; St Clair et al., 2004; Van de Putte et al., 2004; Weinblatt et al., 2003; Weinblatt
et al., 1999). Consequently, improvement in clinical outcomes has resulted in improved
quality of life for RA patients. To date, there are five FDA-approved anti-TNF agents
for RA: adalimumab (Humira®), certolizumab pegol (Cimzia®), etanercept (Enbrel®),
golimumab(Simponi®),andinfliximab(Remicade®)(Agarwal,2011b).
Crohn’s disease is a chronic inflammation of the gastrointestinal tract that is charac-
terized by abdominal pain, diarrhea, gastrointestinal bleeding, bowel perforations, and
fistulas (Baumgart & Sandborn, 2012). The incidence of Crohn’s disease in the United
States(US)was7.9casesper100,000population(1990–2000);andtheadjustedprevalence
was 174 per 100,000 population (2001) (Loftus et al., 2007; Loftus, Schoenfeld & Sandborn,
2002). In 2009, the average annual age- and gender-adjusted incidence rate of CD among
veterans was 33 per 100,000 population (range: 27–40) (Hou et al., 2013). The age- and
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(Hou et al., 2013). Prior to the widespread use of anti-TNF agents, the average annual
cost per patient in the US was estimated to be $19,237 (adjusted for 2012 $US) with
surgery responsible for a majority of direct costs (55.8%) (Bodger, 2002). However, after
the widespread use of anti-TNF agents, the average annual cost per patient with CD was
$13,699peryear(adjustedfor2012$US)(Kappelmanetal.,2008).
Biologictherapies,suchasanti-TNFagents,forCrohn’sdiseasehaveprovidedclinically
meaningfulimprovementinpatientreportedoutcomeswhilemaintainingremission(Ford
et al., 2011; Hanauer et al., 2006; Louis et al., 2013; Sandborn et al., 2007a; Sandborn et
al., 2007b). As a result, the increased utilization of anti-TNF therapy has shifted costs
from hospitalizations and surgeries to medications. Van der Valk et al. (2012) reported
that medication costs were responsible for 70.9% of total direct costs compared to
hospitalizations- (19.4%) and surgery-related costs (0.6%) in the Netherlands (Van der
Valketal.,2012).Loomesetal.(2011)reportedthattotaldirectcostsincreasedfrom$3,930
to $25,346 (difference of $21,416, P < 0.005) after the introduction of infliximab therapy
(adjustedfor2010$CAN)(Loomesetal.,2011).Currently,therearethreeanti-TNFagents
FDA-approved for the treatment and management of CD: adalimumab, certolizumab
pegol, and infliximab (FDA Office of the Commissioner, 2008, National Digestive Diseases
InformationClearinghouse(NDDIC)).
The Department of Veterans Affairs has a national formulary that is shared with all the
VA medical centers around US and its territories. However, none of the anti-TNF agents
are listed on the VA National Formulary (VANF) as of August 2013. This is important
because the burden of disease in the VA is significant. There have been no reports that
currently investigated the efficacy and safety of anti-TNF agents in the veteran population
forallindications.
Thepurposeofthisstudywastoevaluatetheefficacyandsafetyofanti-TNFagentusein
theVeteransAffairsSanDiegoHealthcareSystem(VASDHS)whoinitiatedtherapyin2010
and2011forallprescribedindications.ParticularattentionwasfocusedonRAandCDdue
toearlyapprovalsinthesetherapeuticareas.
METHODS
This was a single-site, retrospective cohort study that evaluated the efficacy and safety of
anti-TNF agents in a veteran population who initiated treatment between 2010 and 2011
and followed-up for 12 months. The study site was at VASDHS, a 296-bed medical facility
inthe SanDiego County,California witha regionalpatient membershipof approximately
232,000 veterans. VASDHS is part of the Veterans Health Administration (VHA), an
integratedhealthcaresystemintheUS.
Patientswereeligibleforinclusioniftheywere18yearsoldorgreaterandinitiatedonan
anti-TNF agent at VASDHS between 2010 and 2011. The index date was determined to be
thefirstfill-dateoftheanti-TNFagentatVASDHS.
Clinical efficacy was categorized as responder, partial responder, and non-responder
which were determined from chart notes as defined by the provider. Responders were
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of symptoms and clinical assessment by the provider. Partial responders were defined
as any documented report of partial improvement from baseline based on attenuated
but continued symptoms and clinical assessment by the provider. Non-responders were
defined as any documented report of no improvement from baseline based on continued
or worsening of symptoms and clinical assessment by the provider. Two reviewers
independently performed the chart reviews (MB and NM) and any disagreements on
clinicalresponsewereresolvedthroughgroupdiscussion.
Primary indication for the anti-TNF agent was determined through the submission of
non-formulary (or prior authorization) consults which were reviewed by the VASDHS
pharmacy service pharmacoeconomics/formulary group. Anti-TNF agents are listed
as non-formulary in the VHA; therefore, requests for these agents in VASDHS require
a submission of a non-formulary consult. Providers were required to list the primary
indicationforanti-TNFagentuse.Ifmorethanoneindicationwaslisted,thentheprimary
indication was categorized according to the specialty field of the submitting provider.
For example, a rheumatology provider who submitted a non-formulary consult for both
arthritisandpsoriasiswillhavetheindicationcategorizedforRA.
Primary aim evaluated response at 12 months post-index date. A majority of clinical
trails evaluated response at 12 months; therefore, we also followed this convention.
Secondary aims evaluated initial response to anti-TNF agents prior to the 12 months
post-index date, alternative strategy after failure to respond or development of an adverse
drug event to the initial anti-TNF agent, and infection events. Reporting was further
stratified into the top three indications: RA, CD, and psoriasis. Infection events included
anyinfectionthatoccurredaftertheindexdateupto12monthspost-indexdate.
This study received appropriate approvals from the UCSD/VASDHS Institutional
ReviewBoardandtheResearchandDevelopmentCommittee(Protocol#:H120150).
Statistical analysis
Normality testing was performed using Shapiro–Wilk’s test for continuous data.
Descriptive analyses for continuous data were presented as mean, standard deviation, and
median. Discrete data were presented as frequency and percentage. One-way analysis of
varianceandKruskal–Wallistests wereperformedforcontinuousdatawhere appropriate.
Pearson’schi-squaredandFisher’sexacttestswereperformedfordiscretedata.
Logistic regression was performed to evaluate the association between anti-TNF
agents and response controlling for potential confounders. The outcome variable was
transformed into a binary variable in order to perform the logistic regression. Responders
andpartialresponderswerecollapsedinto“Responders”.Non-responderandpatientswho
experienced an adverse drug event were categorized as “Non-responders”. Model fit was
assessed using Hosmer–Lemeshow test. Statistical significance was defined as P < 0.05,
two-tailed. All analyses were performed using IBM SPSS Statistics for Windows, Version
20.0(IBMCorp.,Armonk,NY).
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Baseline
A total of 92 patients met the inclusion criteria. Table 1 summarizes the demographic
variables of the cohort. The average patient was 50 (SD, 16.2) years old, male (N = 77,
84%),non-Hispanic(N = 78,85%),andwhite(N = 68,74%).CDwasthemostcommon
indicationforananti-TNFagent(N = 25,27%)followedbyRA(N = 22,24%),psoriasis
(N = 19, 21%), psoriatic arthritis (N = 13, 14%), other conditions (N = 8, 9%), and
ankylosing spondylitis (N = 5, 5%). The most common comorbid conditions were
hypertension (N = 39, 42%), dyslipidemia (N = 36, 39%), gastrointestinal conditions
excludingCD(N =24,26%),cardiovasculardisease(N =11,12%),anddiabetes(N =11,
12%).Severalpatientswereonprednisone(N = 18,20%)ormethotrexate(N = 15,16%)
at baseline. Less than half of the study patients had previous experience with an anti-TNF
agent (N = 42, 46%), most commonly adalimumab (N = 22) followed by etanercept
(N = 11)andinfliximab(N = 9).
A majority of patients were started on adalimumab (N = 38) and etanercept (N = 37)
followedbyinfliximab(N = 17)between2010and2011atVASDHS(Table2).Therewere
no differences in age (P = 0.141), gender (P = 0.480), ethnicity (P = 0.132), and race
(P = 0.726) between the three anti-TNF agents. No difference in primary diagnosis for
anti-TNF agent use was reported with RA (P = 0.119), psoriatic arthritis (P = 0.167),
ankylosing spondylitis (P = 0.474), and other conditions (P = 0.157) between the
three anti-TNF agents. Infliximab and adalimumab were often used in CD compared
to etanercept (P < 0.0001). Conversely, a majority of patients received adalimumab
to treat psoriasis relative to the other agents (P < 0.0001). There were no statistically
significant difference in comorbidities between the three anti-TNF agents except for
hypertension (P = 0.023), other gastrointestinal conditions other than CD (P = 0.016),
and hypothyroidism (P = 0.020). A majority of patients had tuberculosis screening
(N = 83,90%)andhepatitisBscreening(N = 73,79%)performedatbaseline.
At baseline, methotrexate was only reported by patients who started on etanercept
(N = 8) and adalimumab (N = 7). A small number of prednisone prescriptions were
written at baseline during initiation of etanercept (N = 6), adalimumab (N = 8), and
infliximab (N = 4). Among patients who started on etanercept at the VASDHS, six had
previous experience with it. Similarly, among patients who were initiated on adalimumab
and infliximab at VASDHS, eleven and two patients had a previous history with those
agents,respectively.
Clinical response
The average time to first follow-up visit was 86 (SD, 120) days. At the initial follow-up,
73 (83%) patients responded (responder and partial responder) to therapy (Table 3). At
12 months follow-up, a majority of patients responded (responder and partial responder)
to therapy (N = 65, 71%). After 12 months of follow-up, there were 15 unique cases
(16%)ofinfectionsthatdidnotrequirehospitaladmissions,andthreeadversedrugevents
were reported which resulted in discontinuation of anti-TNF agent therapy. Two of the
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2010–2011.
N 92
Variable Mean SD
Age (years) 49.97 16.23
Body mass index (kg/m2) 28.96 5.49
Aspartate aminotransferase (mg/dL) 24.88 20.35
Alanine aminotransferase (mg/dL) 28.13 25.71
Number Percent
Gender
Male 77 84%
Female 15 16%
Ethnicity
Hispanic 13 14%
Non-Hispanic 78 85%
Unknown 1 1%
Race
White 68 74%
Black 11 12%
Asian 3 3%
Native American/Pacific Islander 2 2%
American Indian/Alaskan Native 1 1%
Unknown 5 5%
Declined 2 2%
Primary Diagnosis
Rheumatoid arthritis 23 25%
Crohn’s disease 24 26%
Psoriasis 19 21%
Psoriatic arthritis 13 14%
Other* 7 8%
Ankylosing spondylitis 5 5%
Comorbid conditions
Diabetes 11 12%
Hypertension 39 42%
Arrhythmia 3 3%
Heart failure 3 3%
Malignancy 7 8%
Chronic lung disease 5 5%
Cardiovascular disease 11 12%
Hepatic disease 3 3%
Renal 5 5%
Gout 5 5%
Hepatitis C 4 4%
Dyslipidemia 36 39%
(continued on next page)
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Number Percent
History of myocardial infarction 2 2%
Gastrointestinal (other than Crohn’s disease) 24 26%
Hypothyroidism 5 5%
Baseline DMARDS
Methotrexate 15 16%
Prednisone 18 20%
Sulfasalazine 9 10%
Plaqguenil 4 4%
Previous anti-TNF agent
Yes 42 46%
No 50 54%
Anti-TNF agent history
Adalimumab history 22 24%
Etanercept history 11 12%
Infliximab history 9 10%
Anti-TNF agent history origin
Community provider 21 23%
Another VA facility 5 5%
Department of Defense 4 4%
Veterans Affairs San Diego Healthcare System 12 13%
Rheumatoid factor result at baseline
Positive 11 12%
Negative 14 15%
Tuberculosis test performed
Yes 83 90%
No 9 10%
Tuberculosis result
Positive 3 3%
Negative 79 86%
Hepatitis test performed
Yes 73 79%
No 19 21%
Hepatitis B surface antigen (+) 27 29%
Hepatitis B surface antibody (+) 1 1%
Hepatitis C antibody (+) 7 8%
Notes.
* “Other” includes ulcerative colitis (N = 5), uveitis (N = 1), and spondylarthropathy (N = 1).
drug events that resulted in discontinuation were infection-related (abscess and surgical
wound);theotherwasformyelosplasticsyndrome.
At 12 months follow up, there was no significant differences in responses between
anti-TNF agents (P = 0.904). In patients initiated on etanercept, 18 (49%) were
responders, 6 (16%) were partial responders, 6 (16%) were non-responders, and 2 (5%)
had an adverse drug event (myelospastic syndrome and surgical wound infection) at 12
months (Fig. 1). In patients initiated on adalimumab, 23 (61%) were responders, 8 (21%)
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2010–2011.
Allgroups Etanercept Adalimumab Infliximab
Number % Number % Number % Number % Chi-square df P-
value
Initialoutcomeatfirstfollow-upvisit
Responder 65 71% 23 62% 27 71% 15 88% 7.764 4 0.101
Partial 11 12% 7 19% 4 11% 0 0%
Non-responder 10 11% 4 11% 6 16% 0 0%
Outcomeat12months
Responder 49 53% 18 49% 23 61% 8 47% 2.169 6 0.904
Partial Responder 16 17% 6 16% 8 21% 2 12%
Non-responder 12 13% 6 16% 4 11% 2 12%
ADR 3 3% 2 5% 1 3% 0 0%
Infectionsafteranti-TNFagentinitiation
Yes 15 16% 5 14% 10 26% 0 0% 6.314 2 0.043
No 77 84% 32 86% 28 74% 17 100%
Figure1 Outcomewithtumornecrosisfactoruseat12months,2010–2011.
were partial responders, 4 (11%) were non-responders, and 1 (3%) had an adverse drug
event(abscess)at12months.Inpatientsinitiatedoninfliximab,8(47%)wereresponders,
2 (12%) were partial responders, 2 (12%) were non-responders, and 0 had an adverse
drug event at 12 months. There were missing data for 5, 2 and 5 patients in the etanercept,
adalimumab, and infliximab groups, respectively. These missing data were considered
missing completely at random; therefore complete-case analysis was appropriate (Little &
Rubin,2002).
Responders were stratified by RA, CD, and psoriasis for each anti-TNF agent (Fig. 2).
In RA, 91% of patients receiving adalimumab were responders compared to 78% with
etanercept.InCD,89%ofpatientsreceivinginfliximabwereresponderscomparedto73%
Bounthavong et al. (2014), PeerJ, DOI 10.7717/peerj.385 11/22Figure2 Outcomesofdifferentanti-TNFagentsstratifiedbythetopthreediseasestates,2010–2011.
Table4 Oddsofresponderrelativetoinfliximab.
Variable B SE OR 95%CI
Crudeanalysis**
Etanercept −0.511* 0.876 0.60 0.108, 3.338
Adalimumab 0.215* 0.912 1.24 0.207, 7.412
Oddsofresponderadjustedforage,gender,andTNFhistoryrelativetoinfliximab***
Etanercept −0.090* 0.979 0.91 0.134, 6.225
Adalimumab 0.613* 1.000 1.85 0.260, 13.098
Age, years −0.064 0.024 0.94 0.895, 0.983
Male 0.351 0.919 1.42 0.234, 8.600
TNF history −0.161 0.646 0.85 0.240, 3.023
Notes.
* Referent is Infliximab.
** Hosmer–Lemeshow test, Chi-square <0.0001, df = 1, P = 1.000.
*** Hosmer–Lemeshow test, Chi-square = 9.670, df = 8, P = 0.289.
with adalimumab. In psoriasis, 100% of patients receiving adalimumab were responders
comparedto64%receivingetanercept.
Infections were reported for 5 (14%), 10 (26%), and 0 (0%) patients in the etanercept,
adalimumab, and infliximab groups, respectively. This difference in infection rates
betweenallthreeanti-TNFagentswasstatisticallysignificant(P = 0.043).
Unadjustedoddsofbeingaresponderwere0.60(95%CI[0.11,3.34])and1.24(95%CI
[0.21, 7.41]) for patients initiated on etanercept and adalimumab relative to infliximab,
respectively (Table 4). Controlling for age, gender, and previous history of anti-TNF
agent use, the odds of being a responder was 0.91 (95% CI [0.13, 6.23]) and 1.85 (95% CI
[0.26, 13.10]) for patients initiated on etanercept and adalimumab relative to infliximab,
respectively.
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At VASDHS, patients initiated on an anti-TNF agent had a high proportion classified as
responder (responder and partial responder) after 12 months of therapy. Reports from
several clinical studies support this observation. Weinblatt et al. (2003) reported that 67%
of patients randomized into adalimumab 40 mg every 2 weeks plus methotrexate for
RA achieved American College of Rheumatology 20% (ACR20) at 24-week follow-up
(Weinblatt et al., 2003). Kameda et al. (2010) reported that 90% of patients randomized
intoetanercept25mgtwiceweeklyforRAachievedACR20at24-weekfollow-up(Kameda
et al., 2010). Colombel et al. (2010) investigated the efficacy of infliximab 5 mg per kg plus
azathioprineinCD overa30weekperiod andreportedaremissionrate of57%(Colombel
et al., 2010). Sandborn et al. (2007b) evaluated the long-term effectiveness of adalimumab
40 mg weekly and 40 mg every other week over 56 weeks in moderate-to-severe CD
(Sandborn et al., 2007b). Remission was maintained in 83% and 79% of patients taking
adalimumab 40 mg weekly and adalimumab 40 mg every other week, respectively
(Sandbornetal.,2007b).
Ng, Chu & Khan (2013) performed a retrospective cohort study of biologic utilization
forRAintheVApopulationfrom 1999 to2009(Ng,Chu&Khan,2013).Biologicsusedas
the first DMARD increased from 3% in 1999–2001 to 6.7% in 2006–2007 (P < 0.001)
(Ng, Chu & Khan, 2013). However, the proportion of patients who had a biologic
dispensedforRAwasstableovertheyearsrangingfrom18.6%to26.7%(Ng,Chu&Khan,
2013). We reported that 17% of patients who initiated etanercept previously had been on
an anti-TNF agent; and 90% of patients who were initiated on adalimumab at VASDHS
had previous experience with an anti-TNF agent. We adjusted for this in the logistic
regression model and found that there was no significant confounding with previous
history of anti-TNF agent use on the exposure-outcome relationship. A concern with
previous anti-TNF agent use is confounding by indication where patients are inherently
different due to severity of their disease which results in residual confounding (Salas,
Hofman & Stricker, 1999). Future studies will need to address whether previous history of
anti-TNFtherapyhasanimpactonoutcomesat12monthsfollowup.
Utilization of anti-TNF agents in the CD veteran population has not been previously
performed. However, an evaluation of hospitalization associated with CD in veterans was
performed by Sonnenberg and colleagues (Sonnenberg, Richardson & Abraham, 2009).
From 1975 to 2006, the total number of hospitalizations associated with CD among
veterans was 54,271 with the highest proportion in the 54–64 year age group (N = 22,
551) (Sonnenberg, Richardson & Abraham, 2009). The incidence rate for hospitalization
was11.63per1millionpopulation(Sonnenberg,Richardson&Abraham,2009).Amongthe
veteran population, CD is a moderately severe chronic disease that has modest resource
consumption. However, the use of anti-TNF agents increases the overall direct costs
associated with CD. Our results provide real world effectiveness of anti-TNF agents on
CD in the veteran population; however, we did not evaluate whether the strategy was
based on a top-down or step-up approach (D’Haens, 2009; Hanauer, 2003; Lin, Blonski &
Lichtenstein, 2010). Debate continues on whether a top-down approach is more effective
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2009;Hanauer,2003;Lin,Blonski&Lichtenstein,2010).
We reportedon anti-TNFagent use acrossa widespectrum of different indications.We
also presented the effectiveness of anti-TNF agents for the top three indications: RA, CD,
and psoriasis, but small sample size prevented us from performing additional statistical
tests. The high proportion of patients who were responders for RA, CD, and psoriasis
providesomesupportfortheeffectivenessofanti-TNFagentsat12monthswhichparallels
the results of other studies (Breedveld et al., 2006; Colombel et al., 2010; Colombel et al.,
2007; Kameda et al., 2010; Sandborn et al., 2007b; Weinblatt et al., 2003; Weinblatt et al.,
1999). Justification for using anti-TNF agents for these three indications will require
a more robust analysis with a larger veteran population along with cost-effectiveness
analyses.
Developing infection is a risk associated with using anti-TNF agents. Lane, et al.
reported that VA patients using anti-TNF agents for RA from 1998 to 2005 were at risk of
beinghospitalizedforaninfection[HazardRatio(HR)=1.24;95%CI[1.02,1.50]](Lane
et al., 2011). Ford & Peyrin-Biroulet (2013) reported that patients using anti-TNF agents
for CD had higher risk of developing an opportunistic infection compared to placebo
[Relative Risk (RR) = 2.05; 95% CI [1.10, 3.85]] (Ford & Peyrin-Biroulet, 2013). The
risk of developing Mycobacterium tuberculosis was higher but not significant in patients
receiving anti-TNF agents compared to placebo (RR = 2.52; 95% CI [0.62, 10.21]) (Ford
& Peyrin-Biroulet, 2013). We reported that patients on etanercept and adalimumab
developed infections; however, these did not require hospitalizations and were treated
with oral antibiotics in the outpatient setting. Furthermore, two infection-related adverse
events resulted in discontinuation of the anti-TNF agents. Lane et al. (2011) reported
that patients receiving infliximab for RA had a higher hazard of hospitalized infections
relativetoetanercept(HR=1.51;95%CI[1.14,2.00]);andpatientsreceivingadalimumab
had a lower but non-significant hazard of hospitalized infections relative to etanercept
(HR=0.95;95%CI[0.68,1.33])(Laneetal.,2011).Inourstudy,wereportedthatpatients
in the adalimumab group had more infections compared to the etanercept group; and no
infections were reported in the infliximab group. This conflict may be due to the small
sample size which potentially introduces type II error. Furthermore, Lane et al. (2011)
focused on hospitalized infections in RA while our report described non-hospitalized
infection events for all anti-TNF agent indications. In our study, stratifying by RA, we
observed that 2 out of 7 patients receiving adalimumab developed an infection; however,
infections were not observed in the other groups for RA (data not presented). Future
studieswillneedtoincorporatealargersamplesizeinordertocaptureanyinfectionevents
stratifiedbydisease.
Our study has limitations that are inherent to observational studies and studies
involving chart reviews. This was a retrospective study that used manual chart reviews
to abstract the relevant data. Consequently, there may be some validity issues with how
responders and non-responders were determined. Published studies use standardized
and validated criteria (ACR, DAS, and CDAI) to generate an objective score for a disease
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be impractical. As a result, manual chart reviews are often necessary to determine
response to therapy. Previous studies have demonstrated that manual chart reviews
may be more sensitive in identifying cases of RA compared to using electronic medical
record or ICD-9 coding (Liao et al., 2010; Love, Cai & Karlson, 2011; Tinoco et al., 2011).
However, interpretation of the meaning and intention of the chart notes require careful
attention to the signs and symptoms of disease and improvement in patient functionality.
Misclassification may pose a potential source of internal validity; therefore, we took
precautions and used two independent chart reviewers to mitigate this problem. This
example highlights an important limitation with using chart review in determining
response. Due to a lack of objective reporting, evaluation of success with anti-TNF agents
would be reduced to evaluation based on a case definition of response. We acknowledge
that misclassification is an important bias that cannot be truly ruled out. Ideally, an
objective measurement should be recorded in the patient’s chart; however, this has not
been a requirement for reimbursement or continuation of anti-TNF agents. Future policy
developmentmayconsiderthisasaneedinordertoaccuratelyreportresponseinpatients
receivingthesecostlyagents.
We focused on a single site, which may not be generalizable to other VA institutions.
Although each VA medical center abides by the VHA National Formulary, differences
in practice may exist at individual sites. A lack of a VA national criteria or guideline for
anti-TNF agents in RA and CD has led some sites to develop their own local criteria for
use. These criteria may differ resulting in a variety of methods for providers to get access
to anti-TNF agents for prescribing. In addition, our study focused on a single VA medical
center population which limits generalizability to the general veteran population. Future
studieswillneedtoincorporatetheentireVApopulationusinganti-TNFagentstoconfirm
ourfindings.
This study had missing data, which is a concern, especially if the missing data is
informative. We chose to assume that the missing data was not informative. This does
not rule out the possibility that bias exists. Caution should be applied when extrapolating
what potential effect these missing data would have on the overall conclusion of this
observationalstudy.
Patients who were categorized as non-responders could have been switched to another
anti-TNF agent, continued on the anti-TNF agent, or discontinued altogether. It was not
possible to establish the average time that these patients were on an anti-TNF agent due
to these issues. We reported that the average time to follow up was 86 days, which may
not reflect the average follow up in the community. Further observational studies should
evaluate the average time to follow up with anti-TNF agents in order to establish the
optimaltimetomeasureefficacyandsafety.
We reported that several patients were on DMARDs at baseline. However, due to the
small sample size, we were unable to evaluate whether they were meaningful differences
with this population in terms of effectiveness and safety. Future studies should investigate
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reported.
Finally, patients at the VA may have dual care with non-VA medical centers and
providers. These patients may have experienced changes in their therapy and received
treatment for infections that were not captured with the VA electronic records. Clinical
trialshavereportedtheproportionofpatientswithinfectionsrangingfrom5.7%(Emeryet
al.,2009)to46%(Colombeletal.,2010).Tocomplicatematters,patienthealthcarebenefits
may not be restricted to the VA resulting in patients “shopping” for different providers.
Thismayleadtovitalinformationaboutthepatient’sdiseaseandstatusthatarenotshared
withtheVA(Nayaretal.,2013a;Nayaretal.,2013b;Weeks,Yano&Rubenstein,2002).Asa
result,theremaybesomeunderreportingofinfectioneventswithouranalysis.
WedidnotobservegolimumabandcertolizumabpegolutilizationatVASDHSbetween
2010 and 2011, despite their availability. We speculate that this was due to their novelty,
lack of provider experience, and availability of alternative biologic agents (e.g., IL-6
inhibitors and integrin inhibitors). Although these other anti-TNF agents were not used
at VASDHS, it is possible that they may have been utilized at different VA facilities. Future
studies will need to expand this investigation to include more VA facilities in order to
capturegolimumabandcertolizumabpegolutilization.
CONCLUSION
A majority of patients who were initiated with an anti-TNF agent in the VA were
categorized as responders at 12 months follow-up. This was observed for RA and CD
indications. Infections were only observed in etanercept and adalimumab patients;
however, low sample size in the infliximab subgroup may introduce type II error.
Future studies will need to investigate the entire VA population using anti-TNF agents
todetermineifresponseisconsistentwiththosereportedatVASDHS.
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